You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Imaging Bacterial Infections in Vivo: First in Man Studies
SBC: Microbial Medical, Inc. Topic: NIAIDProject Summary/AbstractInfection is the major complication of virtually all medical devices. It is estimated that 2 million patients acquire a nosocomial infection in the US every year and the CDC estimates that the financial impact of these infections exceeds 5 billion dollars annually. At least half of these infections are directly associated with medical devices. Most commonly, the diagnosis o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Novel Nasal Formulations Containing EC16 for Minimizing COVID-19-Associated Anosmia
SBC: CAMELLIX, LLC Topic: NIDCDProject Summary/Abstract SARS-CoV-2 infection is associated with high mortality and morbidity worldwide. A common sequela is anosmia, the loss of the sense of smell, which can impact the quality of life severely. This is due to the robust replication of SARS-CoV-2 in the nasal neuroepithelial cells, leading to acute or chronic olfactory dysfunction (anosmia). A significant number of patients in th ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Disseminable Evidence-Based Treatment for the Dental Office: Virtual Exposure Tools for Dental Fear- neVR Fear the Dentist
SBC: VIRTUALLY BETTER INC Topic: NIDCRPROJECT SUMMARY/ABSTRACTEach year over 20 million adults with moderate fear and over 14 million adults with severe fear visit the dentist. Because fear portends poor future oral health, patients with dental fear come to experience their worst fears: pain, surgical procedures, and the need for more frequent dental visits. Avoidance is the natural and reinforced response, ironically guaranteeing a r ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 435- PHYSIOLOGICAL COMPRESSION THERAPY TO AUGMENT LYMPHATIC FUNCTION AND IMPROVE LYMPHEDEMA RESOLUTION.
SBC: Lymphatech, Inc Topic: 435LymphaTech seeks to develop a novel lymphatic physiology-based, feedback-controlled intermittent pneumatic compression (IPC) device for the treatment of secondary lymphedema. While compression therapy has been the primary treatment for lymphedema patients for decades, there have been minimal innovations in approaches that leverage compression therapy. In contrast to this, there have been substanti ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
DIGITAL TOOLS AGAINST MISINFORMATION ABOUT INFECTIOUS DISEASE TREATMENTS AND VACCINES
SBC: THE SIMPLE VUE LLC Topic: 112To develop digital tools to identify and combat malicious digital bots that spread misinformation about infectious disease treatments and vaccines, including COVID-19 vaccines.
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPING A NOVEL NON-VIRAL NANOPIECES GENE DELIVERY SYSTEM FOR AD GENE THERAPY
SBC: Nanode Therapeutics, Inc. Topic: 4To develop a new, safe, and efficacious non-viral gene delivery system crossing the blood-brain barrier (BBB) for gene therapy of Alzheimer’s Disease (AD).
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
THE GOAL OF THE PROPOSED PROJECT IS TO DEVELOP AN HIV VACCINE PLATFORM FOR DELIVERY OF HIV ENV IMMUNOGEN THAT PRESENTS ANTIGEN AS NATIVE CONFORMATION
SBC: Genecure LLC Topic: 101Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines: Efforts towards the development of an efficacious HIV vaccine have focused on improvements in the design of the HIV envelope (Env) immunogen for induction and generation of broadly neutralizing antibody (bNAb) responses and novel platforms for immunogen delivery. The goal of this program is to develop an HIV vac ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a protein drug for pancreatic cancer treatment
SBC: ProDa BioTech L.L.C. Topic: 102Abstract Pancreatic cancers are devastating diseases with five year survival rate less than 9%. Currently, there is no effective treatment for advanced disease. One major barrier to efficacy of anti-tumor therapeutics is the dense desmoplastic stromal response. Evidence suggests that cancer associated pancreatic stellate cells (CaPSC) produce the stromal collagen. The ECM laid down by CaPSC is con ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
CDK2 inhibitors for protecting hearing loss
SBC: TING THERAPEUTICS LLC Topic: NIDCDCDK2 inhibitors for protecting hearing loss Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However cisplatin anticancer therapy causes high frequency hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection fr ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
ToxIndex-CPG: Machine learning driven platform integrating a hazard susceptibility database to quantify chemical toxicity factors, predict risk levels and classify biological responses
SBC: INSILICA LLC Topic: RThe overall global market for toxicology testing was $8.1 billion in 2019 and is expected to reach $27 billion by 2025. As toxicological testing is a pre-requisite step in most product development, it adds significant time and costs, as well as represents human health hazards when key data is not captured. In order to minimize time to market, expense, and animal use, advances in computational biol ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health